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Purpose: The goal of this analysis was to determine the test–retest variability of
functional and structural measures from a cohort of patients with advanced forms of
Stargardt Disease (STGD) participating in the SAR422459 (NCT01367444) gene therapy
clinical trial.
Methods: Twenty-two participants, aged 24 to 66, diagnosed with advanced forms of
STGD, with at least one pathogenic ABCA4 mutation on each chromosome
participating in the SAR422459 (NCT01367444) gene therapy clinical trial, were
screened over three visits within 3 weeks or less. Functional visual evaluations
included: best-corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy
Study (ETDRS) letter score, semiautomated kinetic perimetry (SKP) using isopters I4e,
III4e, and V4e, hill of vision (HOV) calculated from static visual fields (SVF) by using a
184n point centrally condensed grid with the stimulus size V test target. Retinal
structural changes such as central macular thickness and macular volume were
assessed by spectral-domain optical coherence tomography (SD-OCT). Repeatability
coefficients (RC) and 95% confidential intervals (CI) were calculated for each
parameter using a hierarchical mixed-effects model and bootstrapping.
Results: Criteria for statistically significant changes for various parameters were found
to be the following: BCVA letter score (8 letters), SKP isopters I4e, III4e, and V4e
(3478.85; 2488.02 and 2622.46 deg2, respectively), SVF full volume HOV (VTOT, 14.62
dB-sr), central macular thickness, and macular volume (4.27 lm and 0.15 mm3,
respectively).
Conclusions: This analysis provides important information necessary to determine if
significant changes are occurring in structural and functional assessments commonly
used to measure disease progression in this cohort of patients with STGD. Moreover,
this information is useful for future trials assessing safety and efficacy of treatments in
STGD.
Translational Relevance: Determination of variability of functional and structural
measures in participants with advanced stages of the STGD is necessary to assess
efficacy and safety in treatment trials involving STGD patients.
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Introduction
Since mutations in the ABCA4 gene were shown to
be causative of autosomal recessive Stargardt disease
(STGD) by Alllikmets,1,2 multiple publications have
described the classification, general course, genotype–
phenotype variability, and severity of STGD.3–7
Mutations in ABCA4 are associated with a spectrum
of disease phenotypes ranging from minimal macular
involvement with only fleck-like changes to complete
chorioretinal atrophy resulting in a generalized cone–
rod or rod–cone dystrophy.8 A common presentation
is a precipitous loss of central visual acuity in the first
decade of life.9,10 Patients with early-onset disease
(i.e., 10 years of age at onset) typically have more
aggressive progression,7 while patients with later
onset STGD (i.e., 45 years of age at onset)
frequently demonstrate foveal sparing6 with milder
progression. The spectrum of severity of STGD has
been explained by a wide variety of biochemical
defects.11 Maugeri et al.5 described a genotype–
phenotype model and proposed a classification of
combined ABCA4 mutations for each patient as
‘‘mild,’’ ‘‘moderate,’’ and ‘‘severe’’ based on the effect
of the mutation on the function of the protein.
There is currently no effective treatment for
STGD, but several phase I/II clinical trials are
underway. These include a gene therapy trial
investigating an Equine Infectious Anemia Virus
(EIAV) based lentivector administered by subretinal
injection, SAR422459 (NCT01367444) as well as a
trial investigating an orally administered vitamin A
analog, C20-D3-vitamin A (NCT02402660).12 With
these potential therapeutics on the horizon, it is
essential to determine the test–retest variability for
the ophthalmic tests commonly used to evaluate
disease progression in the severely affected patients
likely to enter these early phase trials. Test–retest
variability is typically assessed by measuring test–
retest repeatability, which has been reported in many
ophthalmic pathologies such as glaucoma,13,14 X-
linked juvenile retinoschisis (XLRS)15 and retinitis
pigmentosa (RP).16–18 To our knowledge, there is
currently limited information regarding the test–
retest variability in STGD patients in the late stages
of their disease.19,20 These previous studies have
examined repeatability of microperimetry and mul-
tifocal ERG, but there is currently no published test–
retest information regarding visual acuity, visual
fields, and structural measures acquired by spectral-
domain optical coherence tomography (SD-OCT)
for STGD patients.
Typically participants with advanced forms of a
disease are chosen as initial participants for Phase I/II
clinical trials to demonstrate the safety of an
investigational therapy in the early stages of clinical
development. The purpose of the study was to
measure test–retest variability of several commonly
used functional and structural measures in partici-
pants with advanced stages of STGD disease who will
be likely candidates for phase I/II clinical trials.
Materials and Methods
The data from both eyes for screening and baseline
visits prior to treatment in the Phase I/IIa dose
escalation safety study of SAR422459 (NCTO1367444)
was collected and analyzed. The patients were recruited
over a period of 3 years from two sites (Oregon Health
& Sciences University, Casey Eye Institute and Centre
Hospitalier National d’Ophtalmologie des Quinze-
Vingts).The trial conformed to the Declaration of
Helsinki for research involving human participants
and was approved by the Oregon Health & Science
University (OHSU) institutional review boards and the
Comite´ de Protection des Personnes Paris Ile de France
V. Informed written consent was obtained from all the
participants in the study prior to the conduct of any
study procedures.
Participants
The key inclusion criteria for all participants were:
(1) a diagnosis of advanced (moderate to severe)
forms STGD based on the criteria of Lois et al.21 and
Fishman et al.,9 (2) two pathogenic mutations of
ABCA4 with confirmed parental segregation, and (3)
visual acuity less than or equal to 35 to 50 Early
Treatment Diabetic Retinopathy Study (ETDRS)
letter score in the worse eye.
Key exclusion criteria were (1) media haze, (2)
aphakia or prior vitrectomy, (3) other diseases
affecting the visual function (e.g., glaucoma, optic
neuropathy, active uveitis, retinopathy, and maculop-
athy other than Stargardt), (4) myopia greater than 8
diopters (D) spherical equivalent, (5) history of ocular
surgery within 6 months, (6) concomitant systemic
disease in which the disease itself, or the treatment for
the disease, could alter ocular function. During the
screening and baseline study visits, all participants
had a full ophthalmic examination including biomi-
croscopy, funduscopy, fundus autofluorescence
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(FAF), full-field ERG as well as the tests analyzed in
this publication. All patients had central choriocap-
illaris and RPE atrophy on the fundoscopic exami-
nation (Fishman stages III and IV).22 With FAF, six
patients had type A phenotype with central hypo-
fluorescence surrounded by a hyperfluorescent ring.4
A majority of patients (16) demonstrated type B
phenotype with only central hypofluorescence with-
out surrounding hyperfluorescence4 (Fig. 1).
Procedures
BCVA, static, and kinetic perimetry were mea-
sured in triplicate (sessions 1, 2, and 3) and SD-OCT
was performed twice at the screening and baseline
visit (sessions 1 and 2). The visits were a maximum of
3 weeks apart and a minimum of 1 week apart. Data
with no numerical value (e.g., zero letters read for
BCVA) on two of three tests were excluded from the
analysis to lessen the possibility of the underestima-
tion of test–retest variability due to a floor effect.
Visual Acuity
BCVA was measured using the ETDRS chart on
the electronic visual acuity tester (EVA) at a distance
of 3 meters and recorded as the number of letters
read.23 The right eye was tested prior to the left eye.
For subjects with poor central vision, it was suggested
that the subject fixate eccentrically or turn or move his/
her head in any manner that improved visual acuity. If
the subject employed these maneuvers, the technician
ensured that the fellow eye remained covered. Subjects
were also instructed not to lean forward.
Static and Kinetic Perimetry
Both static and kinetic perimetry were performed
using the Octopus 900 Pro (Haag-Streit International,
Koeniz, Switzerland) with Eye Suite i4.000 software
(Haag-Streit International, Koeniz, Switzerland). The
background illumination of the cupola of the Octopus
900 during the testing was 10 cd/m2 (31.4 apostilbs).
Data from static perimetry testing was collected
using a custom designed grid (STGD-RP 184n) with
stimulus size V, the GATE strategy and a centrally
condensed grid of 184 points extending from 568
nasally to 808 temporally. The grid used in this study
was of radial design with the closest interstimulus
distance centrally and interstimulus intervals increasing
with eccentricity toward the periphery. In general, the
interstimulus distance increased progressively with
increasing eccentricity with the points within the
central 308 placed for as even coverage as feasible to
accommodate the large central scotomas seen with
moderately advanced Stargardt disease. Of the 184 test
locations in this grid, 108 occur within 308 radius from
fixation. The interstimulus interval within the central
58 radius of the grid is 2.828438 between points at the
obliques of 458 to 2258 and 1358 to 3158. The
interstimulus interval at the 108 and 208 radius was
5.28 and 5.88, respectively. At the 308 radius, the
interval varied from 6.28 to approximately 10.38.
Beyond the 308 radius, the grid becomes notably looser
with interstimulus intervals of about 17.48 at 55.58
radius from fixation (superiorly and nasally) and
approximately 258 at 808 from fixation (temporally).
However, as can be seen in the illustration of the grid,
staggering of the successive rings of stimulus points
effectively reduces the overall stimulus interval to its
nearest neighbor. Thus, the test grid was designed with
condensation of test locations within the central field
for better definition and resolution of central scotomas
of relatively small to large size. This graded conden-
sation was extended to 308 to enable definition of large
central scotomas (Fig. 4D). The data from this testing
Figure 1. Representative images that demonstrate FAF (A, C) and the fundus appearance (B, D) from 42-year-old patient (A and B) and
40-year-old patient (C and D) with advanced STGD both associated with the homozygote mutation on ABCA4 (missense). Image A
demonstrates FAF phenotype type A with central hypofluorescence surrounded by a ring of hyperfluorescence. Image C demonstrates
FAF phenotype type B with only central hypofluorescence without surrounding hyperfluorescence.
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was then used to measure retinal sensitivity as a hill of
vision (HOV) at 908 as a volumetric estimate of retinal
sensitivity, by using visual field modeling and analysis
(VFMA) software reported by Weleber et al.24
Data from SKP was collected using stimulus test
size V4e, III4e, and I4e and the total seeing area was
calculated for each isopter (seeing area minus defined
scotoma). Test vectors were presented to the partic-
ipants approximately every 158, at an angular velocity
of 48/second, and originating approximately 108
outside the age-correlated normal isopter. Any
scotomas (nonseeing areas within a seeing area) were
mapped using an angular velocity of 28/second,
originating from the assumed center and using at
least 12 vectors. Mapping of the blind spot was done
with the I4e test size target. The technician instructed
participants to look straight ahead and constantly
monitored patient fixation and eye movement
throughout the testing. The program discontinued
stimulus presentation in case of eyelid closure or
fixation breaks. The technician adjusted the subject’s
eye and head position as needed throughout testing.
Optical Coherence Tomography
After pharmacological dilation (Tropicamide 1%)
macular images were obtained of both eyes with the
Heidelberg Spectralis SD-OCT system (Heidelberg
Engineering, Heidelberg, Germany). High speed 97
horizontal line volume scans centered on the fovea
were performed in duplicate at screening and baseline
visits within a 2- to 3-week interval. The horizontal
and vertical line scans were acquired at 308 magnifi-
cation and centered on the fovea. All images were
obtained with the Heidelberg Spectralis active eye
tracking feature, which allows imaging of the same
part of the retina during follow-up exams. The first
examination was marked as the reference and the
follow-up mode, the special feature of the Heidelberg
Spectralis SD-OCT system allowing to scan the same
part of the retina, was used for follow-up visits.
OCT scan quality was assessed for the use of image
averaging, centering of the scan on the fovea, and that
the internal limiting membrane (ILM) and Bruch’s
membrane (BM) were clearly visible permitting manual
segmentation, if needed. ETDRS grids were manually
centered on the fovea of the initial volume scans by
assessment of the component b-scans. Automatic
transfer of the ETDRS grid position by the Spectralis
software ensured that identical areas were measured on
the follow-up scan. Manual segmentation, based on
previously published algorithms, was performed to
correct automated segmentation errors for boundaries
of the ILM and BM.25,26 Mean central thickness
measurements (central circle of 1-mm diameter) and
total macular volume were calculated in the macula by
using a circular ETDRS grid.
Statistical Analysis
The R statistical language was used to perform all
statistical analyses (http://www.r-project.org). Repeat-
ability coefficients (RC) and 95% confidential intervals
(CI) were calculated for each parameter by using a
hierarchical mixed-effects model27 and bootstrapping
method. Data from both eyes were included. Non-
parametric bootstrap samples were drawn 1000 times
for each test. A mixed-effects model was fitted to each
bootstrapped sample set to estimate within-patient SD
and the corresponding RC values. A mixed model can
account for potential correlations among measure-
ments within each eye within a patient. The RC is
defined as 2.773 or (1.96 3=2) 3 within-patient SD
(i.e., 1/2 length of 95% CI of the changes between two
measurements). Dot plots were used to display the
changes between two measurements of the same eye
within a patient and the bootstrapping estimates of RC
coefficient and their 95% bootstrapping CI.
Results
Demographics of the study subjects are summa-
rized in Table 1. The mean age (6SD) of participants
Figure 2. Change in BCVA measured at initial (1) and follow-up
visits (2 and 3). The red solid lines show the RC estimated by
bootstrapping model (8.05 letter score). The data points represent
44 eyes from 22 participants. The blue dotted lines show the lower
and upper 95% CI bound (9.52 and 6.63 letters score).
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was 41.8 6 12.6 years, ranging from 24 to 66 years.
All the subjects were unrelated with the exception of
two subjects who were siblings. See Supplementary
Table S1 for a list of mutations.
Repeatability Coefficient and Confidence
Intervals
The repeatability coefficients were: BCVA (8.05
letter score), SKP isopters I4e, III4e, and V4e
(3478.85; 2488.02, and 2622.46 deg2, respectively),
full HOV VTOT (14.62 dB-sr), central macular
thickness and macular volume (4.27 lm and 0.15
mm3, respectively). The RCs and associated CIs are
summarized in Table 2.
Visual Acuity
The mean BCVA (6SD) was 25 6 11 ETDRS
letters score (Snellen equivalent 20/320), ranging from
6 to 45 letters. There was no significant difference in
right versus left eyes in BCVA, paired t-test, P¼ 0.79.
Figure 2 shows changes in BCVA between three visits
relative to the initial visit for all subjects. The data
points represent 44 eyes from 22 enrolled participants.
The RC (red lines) estimates the criteria of significant
Figure 3. Change in HOV static perimetry VTOT (A), SKP I4e (B), SKP III4e (C), and SKP V4e (D) measured at initial (1) and follow-up visits
(2 and 3). The data points represent 44 eyes from 22 participants. The red solid lines show the RC estimated by bootstrapping model and
the blue dotted lines show the lower and upper 95% CI bound (18.49 and 11.09 dB-sr).
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change as 8.05 letter score with the 95%CI as 9.52 and
6.63 letters score (dotted blue lines.)
Visual Fields
The mean SKP area measured for isopters I4e,
III4e, and V4e and areas of HOV calculated from
static visual fields are summarized in Table 3. Figure 4
shows changes in Full HOV of the static perimetry
and SKP between three visits relative to the initial
visit for all subjects. Criteria for statistically signifi-
cant changes were found to be the following: SKP
isopters I4e, III4e, and V4e (3478.85; 2488.02 and
2622.46 deg2, respectively) and full HOV, VTOT (14.62
dB-sr). Table 2 summarizes the RCs and associated
Figure 4. Representative images showing intervisit variability of static perimetry from 25-year-old patient with advanced Stargardt
disease associated with the homozygote mutation on ABCA4 (deletion) by using the volume of the HOV model between session 1 (A), 2
(B), and 3 (C). (D) Shows the custom 184n grid pattern for the session 1 on the same patient; (E) generated incremental color coded plot
for the session 1 on the same patient.
Table 1. Subjects’ Demographics
Demographics Value
Age, mean 6 SD (range) 42 6 13 (24–66)
Refraction error (range), D 6.75 to 5.25
BCVA, mean 6 SD (range), letters score 25 6 11 (6–45)
Full HOV. VTOT (static perimetry) mean 6 SD (range), dB-sr 61.13 6 28.39 (0.54–106.73)
SKP I4e isopter mean 6 SD (range), deg2 5768.23 6 2653.33 (38.4–10,258.6)
SKP III 4e isopter mean 6 SD (range), deg2 9115.71 6 2736.93 (649.4–12,568.7)
SKP V4e isopter mean 6 SD (range), deg2 11,156.87 6 2666.02 (323.8–14,821.4)
OCT CMT mean 6 SD (range), lm 107.72 6 33.38 (62–189)
OCT MV mean 6 SD (range), mm3 6.05 6 1.11 (4.62–7.27)
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CIs. The RC and CIs for isopter I4e were greater than
for isopters III4e and V4e (demonstrated on Figs. 3B–
D). The RC values were very similar between isopters
III4e and V4e. Figure 4 shows representative images
of intervisit variability observed in the static perim-
etry by using volumetric measure, VTOT, (in dB-sr) of
the HOV model, which is displayed just beneath and
to the left of each model. There was no statistically
significant difference between the sessions (P¼ 0.2 or
more). The mean values between the sessions are
summarized in Table 3.
Variability in CMT and MV Measured by SD-
OCT
All enrolled subjects showed the typical STGD
outer retinal atrophy with foveal involvement. Only
three subjects out of 22 had any of the EZ-band
visible within the horizontal and vertical line scan.
The follow-up mode was only used for 10 of 22
enrolled subjects, data that were not acquired in the
follow-up mode due to patient’s nystagmus or lack of
cooperation were excluded from the analysis. All of
the volume scans for all participants required manual
correction. Misidentification and incomplete segmen-
tation of BM and ILM were present for almost all
lines within the volume scans and were manually
corrected. Figure 5 shows changes in central macular
thickness and macular volume measured by SD-OCT
between two visits relative to the initial visit. The data
points represent 20 eyes from 10 participants. The RC
(red lines) estimating significant change for CMT was
4.27 lm and for MV was 0.15 mm3.
Discussion
We have described test–retest variability of com-
mon functional and structural measures in patients
with advanced forms of STGD related to mutations
of ABCA4, in the cohort of patients with advanced
STGD enrolled in the SAR422459 (NCT01367444)
gene therapy clinical trial. A statistically significant
change in BCVA was calculated to be a change of 8
letters. Interestingly, the significant change in BCVA
is similar to previously published data by Grover at
el.28 reporting seven letters as a significant change in
BCVA in subjects with RP. Jeffrey et al.15 reported a
change between four and eight letters in patients with
XLRS using a similar statistical method. For com-
parison, Arditi at el.29 concluded that 4.5 letters was a
limit for a significant change in visual acuity in
trained healthy participants. Vanden Bosch at el.30
reported a change of 3.5 letters or more on the
ETDRS chart is significant in participants with
macular disease and age-matched healthy subjects;
the difference in test–retest variability between
Table 2. Repeatability Coefficients
Parameter Sample Size RC
95% CI of RC
(Upper and Lower)
BCVA, letter score 22 8.05 6.63–9.52
Kinetic I4e isopter, deg2* 22 3478.85 2028.14–5418.34
Kinetic III4e isopter, deg2 22 2488.02 2042.88–2907.17
Kinetic V4e isopter, deg2 22 2622.46 1934.20–3483.25
Full HOV;VTOT, dB-sr* 22 14.62 10.89–18.35
OCT CMT, lm 10 4.27 2.93–5.88
OCT MV, mm3 10 0.15 0.10–0.20
* Floor effects excluded.
Table 3. Visual Field Mean Values between the Sessions
Parameter
Sessions
1 2 3
Full HOV (VTOT) mean 6 SD, dB-sr 61.13 6 28.39 61.98 6 29.19 65.59 6 28.83
SKP I4e isopter mean 6 SD, deg2 5768.23 6 2653.33 6766.99 6 3149.53 7160.65 6 3111.45
SKP III 4e isopter mean 6 SD, deg2 9115.71 6 2736.93 9267.89 6 2612.78 9640.61 6 2705.34
SKP V4e isopter mean 6 SD, deg2 11,156.87 6 2666.02 10,803.02 6 25.12.13 11,040.15 6 2607.16
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normals and patients in that study were not statisti-
cally significant.
To our knowledge, there is no currently published
data on the variability of VF sensitivity in patients
with STGD. Our study found the criteria for
significant change for SKP isopters V4e, III4e, and
I4e, were 2622.46, 2488.02, and 3478.85 deg2 (ap-
proximately 24%, 27%, and 60% change of the total
field), respectively. The values for the smallest test
target I4e had the highest test–retest variability, which
might be explained by the relatively low visual acuity
of our subjects. Bittner et al.16 examined variability of
Goldmann visual field (GVF) for test targets III4e
and V4e in 37 patients with RP and reported the
variability percentage change ranged up to 20%,16
findings that are similar to our data. Grobbel et al.31
assessed test–retest variability on three separate
sessions of full-field kinetic perimetry with Octopus
900 on 14 healthy subjects. The test–retest variability
was less than 58. If one assumes a circular visual field
with an average radius as 708 for test targets III4e and
V4e, then the area of the test–retest variability can be
roughly estimated as less than 2200 deg2 (approxi-
mately a 14% change) in healthy subjects.
We report 14.62 dB-sr as a significant change
(approximately a 24% change) for VTOT. Weleber et
al.24 found a RC of 6.29 dB-sr (20.9% change) in a
cohort of 10 patients (mean age 42.1 6 16.5 years)
with RP of varying inheritance types, stages of
disease, and severity. Weleber et al.23 also reported
a RC of 9.81 dB-sr (9.5% change) for a group of 10
healthy controls (mean age 42.1 6 11.7 years).
The above noted variability in functional measures
could arise from several causes. With repeated testing
there could be a learning effect. We did note a slight,
nonstatistically significant improvement in BCVA
and visual field sensitivity from sessions 1 to 3. The
variability of functional measures in patients with
STGD was higher compared with reported data in
healthy participants by using similar test strategies.
This difference in variability could be explained by the
presence of unstable fixation or intratest changes in
the preferred retinal locus (PRL) in STDG popula-
tion. Lack of registration of retinal visual field
sensitivity to the retina is one of the limitations of
these functional measures. Continuous monitoring of
eye position by the technician helps to minimize the
effects of eccentric or variable fixation. However,
unlike microperimetry, standard VF testing does not
produce a data set that is registered to the retina.
Thus, eccentric fixation or use of variable PRLs, each
of which is common in patients with STGD disease,
will increase variability. The central macular thickness
(RC 4.27 lm) and macular volume measures of 0.15
mm3 were very close between the sessions consistent
with the lack of progression of retinal atrophy over
the short time between the sessions. The technician’s
role and patient’s cooperation are very important to
achieve this degree of reproducibility. In this study,
only 10 of 22 participants had OCT acquired in the
follow-up mode so this high reliability is biased by our
selection criteria. Thus, this test might be a challeng-
ing end-point parameter for patients with advanced
STGD as many patient’s fixation will not permit data
Figure 5. Change in CMT (A) and MV (B) measured at initial (1) and follow-up visits (2 and 3). The data points represent 20 eyes from 10
participants. The red solid lines show the RC estimated by the bootstrapping model and the blue dotted lines show the lower and upper
95% CI bound.
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acquired in follow-up mode. Also, all OCT scans
contained segmentation errors such as incomplete
segmentation and misidentifications of retinal bound-
aries. The required manual correction was a very
time-consuming procedure. Similar challenges were
observed in other previously published papers.26 In
less advanced patients, it might be possible to measure
thickness and area of specific subsets of the retinal
layers, but this could not be reliably performed in this
group of patients with advanced disease. The test–
retest variability in central macular thickness and
macular volume using SD-OCT of healthy subjects
has been reported as 6.5 lm and 0.06 mm3,
respectively.32 Compared with the functional changes
the variability of structural changes were less variable
and similar to reported data reported in healthy
individuals.
One of the limitations of our study is the lack of
fixation data. As noted above, fixation is only
coarsely controlled with static perimetry as measured
in this trial. Cideciyan et al.20 using the NIDEK MP1
in participants with STGD reported a RC for the
point-wise sensitivity (PWS) as 4.2 dB. This group has
also reported different fixation types and levels of
eccentricity in STGD patients. It would be interesting
in the future to compare the MP1 sensitivity in
Stargardt patients with their ability to perform static
perimetry, as well as to compare and correlate the
fixation type and eccentricity with the intervisit
variability in visual fields.
This study involved only 22 participants all with
advanced Stargardt disease; thus, one must use
caution when applying our findings to other STGD
populations.
In summary, this test–retest analysis provides
important information necessary to determine if
significant changes are occurring in structural and
functional assessments commonly used to monitor
and evaluate outcomes in patients with advanced
STGD, the patients most likely to be enrolled in phase
I/II interventional studies. These data can be useful
for designing future clinical trials and show the
challenges and importance of performing repeat
testing prior to treatment. Similar analyses should
be performed for patients with different stages of
disease.
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